“We believe this discovery to be a breakthrough that will enable the efficacy needed to treat respiratory infections such as COVID-19, influenza and tuberculosis by enabling the drug deposition into the airways and lungs through aerosol formulations and pulmonary delivery.”
- Mike Farber, Director of Life Sciences at Mountain Valley MD, Inventor
“This is the best interview Agoracom has done in the last ten years. If you want to find out what is possible, watch this powerful, eye-opening and sometimes emotional interview with CEO Dennis Hancock and Director of Life Sciences Mike Farber.”
- George Tsiolis, President of Agoracom
“Embedding Mountain Valley MD’s Quicksome™️ technology into our unique mushroom product formulations has allowed us to create a product line that we believe will be unmatched in its efficacy in the marketplace... The initial consumer testing with our energy and sleep products has been very well received. The precision of this delivery technology allows us to build the functional mushroom business out while simultaneously pursuing a leadership position in the rapidly emerging psychedelic space.”
- Dr. Sanjeev Goel, Chief Medical Officer at Circadian Wellness and Founder of Peak Human Labs.
“This breakthrough is a major game-changer for the future potential administration of Ivermectin, and perhaps other drug and vaccine applications. Applied to Ivermectin, Mountain Valley’s Quicksome technology greatly improved its therapeutic potential.”
- Benjamin Smith, The Dales Report
“The extrapolation of this technology achievement across multiple viral applications could be very significant and has the potential to positively impact human and animal health globally.”
- Dennis Hancock, President & CEO of Mountain Valley MD
“Our study will evaluate the ability of MVMD’s new porous aluminum nanostructures to adjuvant injected IPV, promote dose-sparing, and therefore lower costs, and facilitate mucosal and herd immunity when compared to IPV.”
- Dr. John Clements, Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine
“MVMD has developed a tablet that dissolves easily, with a fraction of the dose, of wonder drug Ivermectin.”
- Jackie Cameron, BizNews
“A needle-free, cost-effective, polio vaccine could be a major step towards global polio eradication. Mountain Valley MD’s Quicksome™ technology has already proven its ability to stabilize and preserve the Inactivated Poliovirus Vaccine (IPV) and I believe that this technology holds great promise in finally delivering a needle-free effective sublingual polio vaccine and probably many other globally needed vaccines as well.”
- Dr. John Clements, Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine
“The FDA’s Polio D Antigen preservation results demonstrate that Mountain Valley MD’s proprietary and patented Quicksome™ low temperature strip manufacturing technology can be successfully applied to heat labile vaccines, complex proteins such as insulin or glucagon, peptides and other molecules and constructs that are sensitive to heat and oxidation.”
- Mike Farber, Director of Life Sciences at Mountain Valley MD, Inventor
“We designed the study with the goal of providing the first in vivo proof of enhanced COVID-19 viral clearance ability using both the oral sublingual product and the intramuscular injection product using MVMD’s Quicksol™ technology.”
- Dr. John Clements, Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine
“With encouraging FDA Polio Lab validation, Mountain Valley MD is continuing work on development of our proprietary vaccine adjuvants for Polio and the necessary pre-clinical trials to demonstrate the unprecedented impact of our Quicksome™ technology.”
- Dennis Hancock, President & CEO of Mountain Valley MD
“MVMD takes existing vaccines and drugs – and delivers them better. Both into the body and by transportation to the world. Way better.”
- George Tsiolis, President of Agoracom
“MVMD’s technology showed greater pharmacokinetic performance, more rapid onset times, with greater drug distribution and stability in the canines trialled—at 1/5 the dosages compared to existing oral and subcutaneous injection solutions.”
- Benjamin Smith, The Dales Report
“For decades scientists have been working to solve the problem of vaccine instability and cold chain distribution with little progress. Approaches such as micro-needle applications, lyophilization, spray drying, and others have not reached commercialization due to problems of complexity, cost, and long-term stability challenges.”
- Mike Farber, Director of Life Sciences at Mountain Valley MD, Inventor
“The transgenic mice model was selected to specifically enable preclinical evaluation of the potential therapeutics and monoclonal antibodies and molecular-based therapeutics as they apply to COVID-19 treatments.”
- Dr. John Clements, Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine
.svg)
